Clinical Trial Update: Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rituximab for refractory adult and juvenile dermatomyositis and adult polymyositis; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis
• Juvenile Dermatomyositis
• Polymyositis

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: University of Pittsburgh | Conditions: Myositis, Dermatomyositis | Phase 2 | Status: COMPLETED | Results posted: 2015-03-04